Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would make Takeda responsible for Phase 3 testing of the therapy, putting AC Immune in line for up to $2.1 billion in milestone payments.
The post Takeda Commits $100M for Chance to Bring Immunotherapy to Alzheimer’s Disease appeared first on MedCity News.
